NKTR-0165
Ulcerative Colitis, Vitiligo, Multiple Sclerosis
PreclinicalUnknown
Key Facts
Indication
Ulcerative Colitis, Vitiligo, Multiple Sclerosis
Phase
Preclinical
Status
Unknown
Company
About Nektar Therapeutics
Nektar Therapeutics is focused on developing transformative medicines that resolve immune imbalances to treat autoimmune and inflammatory conditions. The company's pipeline is anchored by rezpegaldesleukin, a Treg-targeting biologic in advanced Phase 2b studies, and NKTR-0165, a preclinical TNFR2 agonist. With a seasoned leadership team and a history of successful partnerships leading to approved medicines, Nektar is advancing a portfolio of first-in-class candidates with significant disease-modifying potential.
View full company profile